Rodina, Anna
Wang, Tai
Yan, Pengrong
Gomes, Erica DaGama
Dunphy, Mark P. S.
Pillarsetty, Nagavarakishore
Koren, John
Gerecitano, John F.
Taldone, Tony
Zong, Hongliang
Caldas-Lopes, Eloisi
Alpaugh, Mary
Corben, Adriana
Riolo, Matthew
Beattie, Brad
Pressl, Christina
Peter, Radu I.
Xu, Chao
Trondl, Robert
Patel, Hardik J.
Shimizu, Fumiko
Bolaender, Alexander
Yang, Chenghua
Panchal, Palak
Farooq, Mohammad F.
Kishinevsky, Sarah
Modi, Shanu
Lin, Oscar
Chu, Feixia
Patil, Sujata
Erdjument-Bromage, Hediye
Zanzonico, Pat
Hudis, Clifford
Studer, Lorenz
Roboz, Gail J.
Cesarman, Ethel
Cerchietti, Leandro
Levine, Ross
Melnick, Ari
Larson, Steven M.
Lewis, Jason S.
Guzman, Monica L.
Chiosis, Gabriela
Article History
Received: 9 March 2016
Accepted: 2 September 2016
First Online: 5 October 2016
Competing interests
: Memorial Sloan Kettering Cancer Centre holds the intellectual rights to PU-H71, YK-derivatives and uses of labelled HSP90 inhibitors. Samus Therapeutics, of which G.C. has partial ownership, has licensed PU-H71 and PU-PET.